

## Nadia Ahmad, MD, MPH

---

### **Title**

Associate Vice President – Medical Development – CWM - Lilly

### **More About Nadia**

Nadia Ahmad, MD, MPH is the associate vice president of medical development for tirzepatide obesity at Eli Lilly and Company and is responsible for leading the tirzepatide SURMOUNT clinical development program for chronic weight management in people living with obesity.



Nadia joined Lilly in February 2019 as a senior medical advisor of obesity product development. In her role as senior medical advisor, Nadia drove several internal engagement programs in obesity and contributed to cross-functional efforts for obesity strategy, in addition to serving as the lead for two phase 3 SURMOUNT registration trials. Prior to joining Lilly, Nadia was the founding director of the Obesity Medicine Institute in Dubai and held the role of senior advisor of obesity solutions at Johnson & Johnson Middle East.

Nadia earned her medical degree from New York University School of Medicine and completed an Internal Medicine Residency at the University of Pennsylvania. She went on to become an inaugural fellow in the nation's first Obesity Medicine and Nutrition fellowship program at the Massachusetts General Hospital and is currently Clinical Instructor in Obesity Medicine at the Yale School of Medicine. Nadia also holds a Master of Public Health from the Harvard School of Public Health. She is passionate about transforming care for people living with obesity.

###